Starpharma’s dendrimers improve efficacy of docetaxel in animals
1 February 2012
- Starpharma’s dendrimer-docetaxel formulation significantly more effective than leading cancer drug docetaxel (Taxotere®) in breast cancer model
- More than half (60%) of animals treated with Starpharma’s dendrimer-docetaxel formulation had no evidence of tumour at 94 days whereas with docetaxel significant tumour regrowth was observed in all animals
- Starpharma’s dendrimer-docetaxel formulation improved water solubility by 5000-fold